Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

NCT01532362 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
1
Enrollment
OTHER
Sponsor class

Stopped Drug sponsor stopped drug manufacture due to toxicity issues from other studies

Conditions

Interventions

Sponsor

Jonsson Comprehensive Cancer Center